Build
Build a clear and credible FDA 483 response
pharma
Responding Effectively to FDA Form 483 Observations MasterClass - EU edition
26-27 January, 2027
26-27 January, 2027Virtual
MasterClass in Pharma
This two-day live online training provides a practical approach to building effective FDA 483 responses aligned with FDA expectations.
26-27 January, 2027, Virtual
Time Zone: UTC/GMT+1 /CET
Key learnings
FDA expectations
Meet FDA expectations for structure, timing, and content
Assess
Assess observation risk and potential systemic impact
Plan
Plan investigations and root cause analysis effectively
Develop
Develop practical CAPAs with measurable effectiveness checks
Recognize
Recognize response gaps that may increase warning letter risk
Manage
Manage technical disagreement with FDA professionally
Trusted by over 17,000 delegates across leading companies
Overview
FDA Form 483 observations require a timely, clear, and credible response. A weak or incomplete response can increase regulatory concern and may contribute to further enforcement action.
This two-day live online training provides a practical approach to building effective FDA 483 responses aligned with FDA expectations. Participants will learn how to structure a response package, address observations clearly, prepare executive summaries, manage the 15-business-day response window, and document interim actions, milestones, and follow-up commitments. The course also covers risk assessment, investigation planning, root cause analysis, CAPA development, effectiveness checks, and management oversight. Through practical workshops and realistic FDA 483 and warning letter scenarios, participants will learn how to identify response weaknesses, strengthen remediation plans, and reduce escalation risk. The training also addresses how to handle scientific or technical disagreement with FDA observations professionally, using facts, data, and regulatory support.
#masterclass #glceurope #pharmaonlinetraining #globalleadingconferences #fda #483 #fda483
Meet the expert
Trainer
Dr. Peter Riechel
Director at T3 Consulting
Peter is a quality management expert with 25+ years in pharma and biopharma, specializing in quality assurance, regulatory compliance and CMO oversight. With T3 Consulting, he has advised companies on selecting, qualifying, and managing contract manufacturers. His expertise spans Analytical Development, Quality Management Systems, Annex 1 Compliance, and Technology Transfer. A consultant since 2013, Peter delivers practical, risk-based strategies and industry-specific solutions, making him a trusted advisor in contract manufacturing.
Reasons to attend a masterclass
Practical knowledge
Venture into undiscovered territories and gain inspiration through collaboration
Interactivity
Boost your professional skills by directly engaging with domain experts
World-class trainers
Gain value and learn from the best instructors
Networking
Build a top-notch community and advance your career
Recommendation
WHO SHOULD ATTEND
This training is suitable for professionals involved in FDA inspections, inspection response, quality systems, investigations, and remediation, including:
• Quality Assurance and Quality Control professionals
• Regulatory Affairs professionals
• Inspection readiness and audit teams
• Compliance and GMP managers
• Site leadership and quality unit leaders
• CAPA, deviation, and investigation owners
• Manufacturing and operations managers
• Validation and technical operations teams
• Qualified Persons and Responsible persons working wiith FDA-regulated products
• Consultants supporting FDA inspection responses, remediation, or quality system improvements
14+
Years of experience
600+
Events organized
4,000+
Speakers
25,000+
Attendees
Take the next step